The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.
 
Paulo Siqueira do Amaral
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Adicet Bio; Alpine Immune Sciences; Aravive; Arcus Biosciences; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Nimbus Therapeutics; Xencor
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Pionyr (Inst)
 
Gabriel Polho
Travel, Accommodations, Expenses - Libbs
 
Kelvin Moses
Employment - Vanderbilt University Medical Center
Consulting or Advisory Role - Boston Scientific-Data Safety Monitoring Comite
 
Jennifer Gordetsky
No Relationships to Disclose
 
Sam Chang
No Relationships to Disclose
 
Amy Luckenbaugh
No Relationships to Disclose
 
Kristin Ancell
No Relationships to Disclose
 
Morgan Lambrecht
No Relationships to Disclose
 
Kerry Schaffer
Honoraria - MJH Live Events
Consulting or Advisory Role - Bayer; Bayer; Janssen Biotech; Sanofi; Sanofi
Research Funding - Tempus (Inst)
 
Elizabeth Kaiser
No Relationships to Disclose
 
Daniel Joyce
No Relationships to Disclose
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai